Hormone-Free IUD MIUDELLA Shows Strength Through Six Years

A hormone-free IUD may soon last twice as long as the label currently allows. Organon announced on October 16 that interim results from an ongoing Phase 3 study show its copper hormone-free IUD, MIUDELLA, remained effective through six years of use. The company is presenting the data this weekend at the 2026 Society of Family Planning Annual Meeting in San Francisco, and the findings back a pending request to the Food and Drug Administration to extend the device's approved duration of use. If the extension is granted, the hormone-free IUD would become a stronger fit for people who want years of contraception without hormones and without another replacement procedure.

What the six-year data show

The trial is a prospective, single-arm study run by Sebela Women's Health at forty-two sites across the United States, enrolling participants aged seventeen to forty-five. The six-year outcomes covered four hundred sixty-five participants in the pregnancy-efficacy analysis and five hundred ninety-two in the safety analysis. The cumulative Pearl Index over six years was 0.93, with a 95 percent confidence interval of 0.62 to 1.34. The Pearl Index counts pregnancies per one hundred woman-years of use, so a figure below one means fewer than one pregnancy for every hundred years of combined use. The estimated cumulative pregnancy rate by the Kaplan-Meier method was 3.9 percent at six years, with a confidence interval of 2.7 to 5.8 percent, according to Organon's announcement. The company said the six-year results add to the clinical evidence for the hormone-free IUD while the FDA reviews the request to extend its label.

On safety, no new safety signals appeared during the additional three years of follow-up, reported the trade publication Pharmacally. The treatment-emergent adverse events recorded through six years included heavy menstrual bleeding, dysmenorrhea and pelvic discomfort. Bleeding- and pain-related side effects led one hundred thirty-nine participants to discontinue in the first year, compared with eleven by year six, which suggests the heaviest toll on tolerability comes early. Separately, the FDA has accepted for review Organon's supplemental new drug application to extend MIUDELLA's approved duration of use to six years, with a decision expected in the second quarter of calendar year 2027. The device is currently approved for three years of use, and its label carries a boxed warning under a risk evaluation and mitigation strategy aimed at improper insertion by untrained providers, according to the company's safety information.

Why a hormone-free option matters

MIUDELLA is a copper-containing IUD, so it prevents pregnancy without hormones, an option for people who cannot use hormonal methods or prefer not to, for medical reasons or by personal choice. Demand for non-hormonal contraception has been a steady undercurrent in reproductive health, and copper devices are one of the few long-acting methods that fit it. The device was developed by Sebela Women's Health, and in June 2026 Organon licensed the global rights exclusively, folding it into a portfolio built around women's health. That positioning is the whole point of the hormone-free IUD: long-acting contraception with nothing hormonal involved.

If the FDA grants the extension, people using the device could go six years between replacement procedures instead of three. That matters for anyone who has found IUD insertion painful, a complaint that is widely shared in patient accounts, and fewer replacements also mean fewer appointments and less cost churn for people paying out of pocket. A longer label would also bring MIUDELLA closer to the duration of some existing copper IUDs, which are approved for up to ten years, and it would cut the lifetime number of insertion procedures a person using this hormone-free IUD goes through.

There are caveats. The results are interim rather than final, and a single-arm trial has no comparison group, so efficacy is judged against expected pregnancy rates rather than a head-to-head rival. Follow-up in the study is still ongoing. The full presentation takes place on October 17 at the Society of Family Planning meeting in San Francisco, where clinicians will get the detailed breakdown. The trial continues, and the FDA's decision on the extension is expected in the second quarter of 2027. Anyone weighing an IUD can ask a clinician about fit, bleeding changes and the removal process before deciding. The announcement, with full study details, is available from Organon.

Source: Organon announcement via Business Wire, October 16, 2026